Indeed, the advent of CGRP-monoclonal antibodies (CGRP-mAbs), or more recently of gepants, sets up, for the first time, a specific ‘ad-hoc’ approach against neuropeptides with a well-known role in migraine pathophysiology, representing a turning point in migraine preventive treatment due to the high efficacy, safety, and tolerability [7]. Here, CALCA is linked to migraine disorder.